Dantrolene Sodium interactions
Checked as Dantrolene in this data source.
Full monograph for Dantrolene SodiumCheck it against another medicine
Medicines
238 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Conjugated EstrogenCreamTablet | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Conjugated Estrogen + Bazedoxifene | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiol | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Dienogest + Estradiol Valerate | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Drospirenone + Estetrol | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. | 1 sources — open the full entry |
| Drospirenone + Estradiol | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mg | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolate | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Estradiolbasevaginal cream | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Estradiol + Dydrogesterone | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Estradiol Hemihydrate + Progesterone Micronized | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Estradiol Valerate | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mg | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Ethinyl Estradiol + Gestodene | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Ethinyl Estradiol + Lynestrenol0.0375 mg0.05 mg | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Fentanyl Citrate | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Medroxyprogesterone AcetateInjectionTablet | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. | 1 sources — open the full entry |
| Morphine Sulfate | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Nalbuphine Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Norgestrel + Ethinyl Estradiol + Ferrous Fumarate | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Oxymorphone Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Paracetamol + Tramadol Hydrochloride | Major | Synergy · Unknown | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics…2 documented mechanisms | 1 sources — open the full entry |
| Pentazocine | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Pethidine Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Remifentanil Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Tapentadol Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Tramadol Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Alprazolam | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…2 documented mechanisms | 44 sources — open the full entry |
| Amlodipine Besilate | Moderate | Synergy | Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is… | 7 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Synergy | Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is… | 7 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy | Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is… | 7 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Synergy | Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is… | 7 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Synergy | Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is… | 7 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Synergy | Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is… | 7 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Synergy · Unknown | Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is…2 documented mechanisms | 7 sources — open the full entry |
| Aripiprazole | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Asenapine Maleate | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Baclofen | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Synergy | Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is… | 7 sources — open the full entry |
| Brexpiprazole | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Brivaracetam | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Bromocriptine Mesylate | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Carbamazepine | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged release | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 36 sources — open the full entry |
| Cariprazine | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
Food & lifestyle
alcohol
ModerateSynergy
Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
What to do: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
4 sources
- Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc. (1990):
- "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
- "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2015):
Therapeutic duplication
Drug classes that overlap with Dantrolene Sodium, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
muscle relaxants
The recommended maximum number of medicines in the 'muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'muscle relaxants' category.
Example product in the source data (US market): Orphengesic forte
muscle relaxants
The recommended maximum number of medicines in the 'muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'muscle relaxants' category.
Example product in the source data (US market): Soma compound with codeine
muscle relaxants
The recommended maximum number of medicines in the 'muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'muscle relaxants' category.
Example product in the source data (US market): Aspirin/methocarbamol
muscle relaxants
The recommended maximum number of medicines in the 'muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'muscle relaxants' category.
Example product in the source data (US market): Aspirin/carisoprodol